Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Everplay interim revenues fall, FY adjusted EBITDA seen 'slightly ahead' of expectations

(Sharecast News) - Games developer Everplay Group, formerly known as Team17, said on Tuesday that full-year adjusted underlying earnings were expected to be slightly ahead of current market expectations, despite reporting a decline in interim revenues. Revenues fell 10% to £72.4m in the six months ended 30 June, due to the timing of license revenues, new title launches, declines in physically distributed sales and the "very strong" prior year back catalogue performance, while adjusted underlying earnings slipped by 1% to £19.2m. However, gross profits rose 2% to £33.7m, as did adjusted pre-tax profits at £19.7m, while gross profit margins improved from 40.8% to 46.5%.

The FTSE 250-listed group highlighted that new release revenues were expected to be "significantly higher" in H2. Following its trading performance to date, the strong line-up of titles in H225, visibility over license deals later in the year and a favourable sales mix of titles on margins, Everplay expects full year adjusted EBITDA to be "slightly ahead" of current market expectations

Interim executive chairman Frank Sagnier said: "It has been a strong start to the year. The improved performance of our new releases shows the progress we have made continually enhancing our internal procedures, such as our greenlight process, the quality of our production, and our marketing approach.

"Looking ahead, we have a busy second half to deliver, but the team remains laser-focused on performance and delivering on our strategic priorities to ensure continued long-term growth for the Group and our shareholders."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.